ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
This Phase 3, international, multicenter, open-label study will monitor the long-term safety of ambrisentan in subjects with PH. The available ambrisentan doses for this study are 2.5, 5, or 10 mg once daily (qd); the approved doses in the United States, Canada, and the European Union are 5 and 10 mg ambrisentan qd. Investigators will be able to adjust ambrisentan dose as clinically indicated. Ambrisentan can be increased or decreased in one-step intervals, with a minimum of 4 weeks between dose adjustments. Subjects receiving other therapies for PH that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in this study and continue to receive such therapies.
This study is closed to enrollment and in the follow-up phase.
Please refer to www.clinicaltrials.gov identifier: NCT00777920 for more information.